Monitoring bleeding in patients with femoral neck fractures on NOAC therapy during surgery
Bleeding of Patients Using NOAC Anticoagulation Therapy in Proximal Femoral Fracture Internal Fixation Surgery
This study is testing whether it's safe to perform surgery right away on patients with femoral neck fractures who are taking blood thinners, by checking for bleeding during the procedure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Meir Hospital, Kfar Saba, Israel Academic / other |
| Locations | 1 site (Kfar Saba) |
| Trial ID | NCT06644976 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety of performing surgery on patients with femoral neck fractures who are on NOAC anticoagulation therapy without the traditional waiting period. The researchers will monitor bleeding during the surgery and measure the levels of NOAC drugs in the blood. By comparing outcomes with regular patients, the study seeks to determine if earlier surgical intervention is feasible and safe for these patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with femoral neck fractures who are capable of providing informed consent and are on NOAC therapy.
Not a fit: Patients under 18 years old, those on anti-platelet therapy, or with certain medical conditions such as low creatinine clearance or active cancer therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could allow for quicker surgical treatment of femoral neck fractures in patients on NOAC therapy, potentially improving recovery times and outcomes.
How similar studies have performed: While this approach is innovative, similar studies have not been widely reported, indicating that this may be a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: above 18 y.o femoral neck fracture NOAC capable of making inform consent primary surgery \- Exclusion Criteria: * under 18 y.o * anti platelet therapy (aspirin is not included) * creatinine clearance under 50 * active anti cancer therapy * ITP patients * non capable of making inform consent * patients which decide not to proceed with the expeirment
Where this trial is running
Kfar Saba
- Meir Hospital — Kfar Saba, Israel (Recruiting)
Study contacts
- Study coordinator: Meron pinchas talmor, medical doctor
- Email: merontalmor@gmail.com
- Phone: +972523264183
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.